Dr Darren K. Mcguire Discusses Use Of Sglt2 Inhibitors And Glp-1 Receptor Agonists In T2D

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

Dr Darren McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention

Darren K. McGuire | Antihyperglycemic Medications for Cardiovascular Risk Reduction

The Texas Heart Institute

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

Darren McGuire | Cardiovascular effects of diabetes medications: Lessons learned from CVOTs

The Texas Heart Institute

Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits

Safe and Effective Use of SGLT2i's and GLP-1RA's in Your Cardiology Practice

American College of Cardiology

EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes

Endocrine Society

Fundamentals of SGLT2i's and GLP-1RA's for CV Risk

American College of Cardiology

Dr. Darren McGuire | Inside the Studio w/ Dr. Stephanie Coulter

The Texas Heart Institute

ACCEL: Darren K. McGuire, MD

Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?

Cardiovascular Disease Burden in Type 2 Diabetes: Strategies to Improve Outcomes

Interest Regarding Diabetes and CVD Risk

Jeffrey Berger, MD: Deciding Between GLP1 Agonists or SGLT2 Inhibitors

Updates on SGLT2 Inhibitors and GLP-1 Receptor Agonists

GMO Dialogues | Impacts of GLP-1 Receptor Agonists and SGLT-2 Inhibitor on CKD with Dr Frank Maddux

Fresenius Medical Care

Using GLP-1 Agonists & SGLT-2 Inhibitors Together from the Cardiologist's Perspective (SGLT2 & GLP1)

Managing T2D and CVD in Older Adults

American Diabetes Association